Anti-proliferative activity of RIHMS-Qi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases.
Randa El-GamalSara ElfarrashMohammad El-NablawayAsmaa Ahmed SalemSeyed-Omar ZaraeiHanan S AnbarAshraf ShomaMohammed I El-GamalPublished in: BMC cancer (2023)
RIMHS-Qi-23 is exerting an anti-proliferative effect that is more potent and selective than doxorubicin.